NCT06043245 (DIABAR-3) is a NA clinical trial of Duodenal Switch in Severe Obesity, sponsored by Hospital Universitari de Bellvitge.

Who is sponsoring NCT06043245?

NCT06043245 is sponsored by Hospital Universitari de Bellvitge.

What drugs are being tested in NCT06043245?

Interventions in NCT06043245: Duodenal Switch, SADI-S, Minigastric Bypass.

What condition does NCT06043245 study?

NCT06043245 studies Severe Obesity, Diabetes Mellitus, Type 2, Bariatric Surgery Candidate.

Is NCT06043245 still recruiting?

NCT06043245 is currently enrolling by invitation. Last updated 21 September 2023.

Last reviewed 2023-09-21 · How we verify

NCT06043245: DIABAR-3

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Diabetes Remission and Hypoabsorptive Bariatric Surgery

ENROLLING BY INVITATION NA Last updated 21 September 2023

What this trial tests

NA trial testing Duodenal Switch in Severe Obesity in 66 participants. Enrolling by invitation.

Timeline

21 June 2023

Primary endpoint
30 September 2026

30 September 2027

Quick facts

Lead sponsor	Hospital Universitari de Bellvitge
Phase	NA
Status	ENROLLING BY INVITATION
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	66
Start date	21 June 2023
Primary completion	30 September 2026
Estimated completion	30 September 2027
Sites	1 location across Spain

Drugs / interventions tested

Duodenal Switch
SADI-S
Minigastric Bypass

Conditions studied

Severe Obesity — all drugs for Severe Obesity →
Diabetes Mellitus, Type 2 — all drugs for Diabetes Mellitus, Type 2 →
Bariatric Surgery Candidate — all drugs for Bariatric Surgery Candidate →

Sponsor

Hospital Universitari de Bellvitge

Who can join

Adults 18 to 60, any sex, with Severe Obesity or Diabetes Mellitus, Type 2. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Bariatric surgery is the most effective treatment to achieve type 2 Diabetes Mellitus (DM) remission in patients with severe obesity. However, there is little evidence of the effectiveness and pathophysiological mechanisms involved in metabolic improvement after hypoabsortive tecniques such as duodenal switch (DS), single anastomosis duodenal switch (SADI-S) or minigastric bypass (MGB). We have designed a randomized study to compare type 2 diabetes remission after the 3 bariatric procedures in patients with severe obesity (BMI \> 45kg/m2) and to study the implication of gastrointestinal hormones, bile acids and gut microbiota in metabolic improvement in each procedure.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Severe Obesity

Currently open trials in the same condition.

NCT07058155 — Optimizing Portal Hypertension With TIPS and Interval Metabolic Surgery for Advanced Liver Disease · Phase 4 · recruiting
NCT06757296 — Endoscopic Conversion of Sleeve Gastrectomy to Single Anastomosis Sleeve-ileal Bypass (SASI) for Gastroesophageal Reflux · NA · recruiting
NCT06547515 — Bone and Muscle Health Following Sleeve Gastrectomy in Men, Premenopausal and Postmenopausal Women · recruiting
NCT04165694 — Single Anastomosis Duodenal Ileal Bypass (SADI) for Sleeve Revision · NA · active not recruiting

Other Hospital Universitari de Bellvitge trials

Trials by the same sponsor.

NCT07522931 — Morphometric Study of the Female Pelvic and Lower Abdominal Retroperitoneum in Cadavers · recruiting
NCT07155590 — Subphenotype- and Complication-guided Adjunctive Fosfomycin Therapy for Staphylococcus Aureus Bacteraemia · active not recruiting
NCT06653192 — EUS-guided Choledochoduodenostomy vs ERCP as First Line in Malignant Distal Obstruction (CARPEDIEM Trial) · NA · recruiting
NCT07178483 — Evaluation of Physical Capacity and Energy Requirements in Patients With Hypoxemic Acute Respiratory Failure · active not recruiting
NCT06955221 — Effect of Alcohol Sclerotherapy on Pelvic Pain and Quality of Life in Women With Ovarian Endometriosis · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06043245 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Hospital Universitari de Bellvitge
Last refreshed: 21 September 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06043245.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing